Kilimanjaro
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
- NCT05259839 ↗
- Active, not recruiting
- AbbVie
- Focused
We haven't built an HCP commentary report on Kilimanjaro (etentamig, dexamethasone and 3 more in Relapsed/Refractory Multiple Myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on Kilimanjaro so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 | |
| YouTube | 1 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Dose Escalation and Expansion Study of Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Patients With Newly Diagnosed or Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- Etentamig; Dexamethasone; Lenalidomide; Pomalidomide; Daratumumab
- Arms
- Part 1: Arm A (Etentamig with Pomalidomide and Dexamethasone) · Experimental
- Part 1: Arm B (Etentamig with Lenalidomide and Dexamethasone) · Experimental
- Part 1: Arm C (Etentamig with Daratumumab and Dexamethasone) · Experimental
- Part 2: Arm E (Etentamig with Pomalidomide and Dexamethasone) · Experimental
- Enrollment
- 283
- Primary outcomes
- Number of Participants with Dose Limiting Toxicities (DLT) of Etentamig
- Number of Participants with Adverse Events (AEs)
- Sponsor
- AbbVie
- Start
- Oct 20, 2022
- Primary completion
- Sep 2033 (estimated)
- Results posted
- No
- Registry record
- NCT05259839 · updated Aug 14, 2026